Located in Research Triangle Park, North Carolina, the site will service the firm's growing dermatology market
MedPharm, a Guildford, UK-based topical and transdermal drug formulation development specialist, has officially opened a subsidiary in the US.
MP Pharma Services, located in Research Triangle Park, North Carolina, has already completed the first client studies on-site following full equipment and process validation.
The facility will provide access to MedPharm’s unique and novel in vitro models.
The firm says these allow assessment of new drug candidate libraries and formulation performance through efficacy, target engagement and delivery testing in quicker and more reliable ways than previously possible.
'This is an exciting milestone for MedPharm,' said Dr Andrew Muddle, MedPharm's co-founder and CEO.
'Adding local capacity and bringing on board new proprietary testing models and high through-put screens, will give our North and South American clients the best opportunity yet of reaching the market with the innovative products we help develop for them.'
Co-founder and CSO Professor Marc Brown said the new laboratories at Research Triangle Park will enable pharmaceutical companies to test various topical and transdermal formulations such as creams, gels and sprays for both new and existing drugs.
'We have built strong relationships with many of the major US pharmaceutical players and this major investment will enable us to provide our clients with an even faster response to their development challenges, whether it is for new chemical entities, reformulation, generics or claim substantiation,' he said.
Dr Jon Lenn has been appointed as Vice President of MedPharm US.
'We are looking forward to offering clients a host of innovative biological models and automated systems that will greatly de-risk and expedite their development programmes,' he said.